Literature DB >> 28803996

Perioperative hemodynamics and outcomes of patients on metyrosine undergoing resection of pheochromocytoma or paraganglioma.

James J Butz1, Toby N Weingarten2, Alexandre N Cavalcante3, Irina Bancos4, William F Young5, Travis J McKenzie6, Darrell R Schroeder7, David P Martin8, Juraj Sprung9.   

Abstract

INTRODUCTION: To describe outcomes of patients with metyrosine (MET) pretreatment for abdominal surgical resection of pheochromocytoma or paraganglioma (PCC/PGL) compared with patients who had phenoxybenzamine (PBZ) pretreatment.
METHODS: Retrospective review of perioperative outcomes for PCC/PGL patients treated with MET and propensity-matched comparison of MET and PBZ (MET + PBZ) with PBZ alone.
RESULTS: MET preparation was given in 63 cases (26 laparoscopic and 37 open, of which 55 also received PBZ). All patients had wide perioperative hemodynamic oscillations. Patients with open procedures required more intravenous fluids and blood transfusions; 35% required postoperative vasopressor infusions for hypotension and 38% developed acute kidney injury. One laparoscopic procedure required postoperative vasopressor infusion, and 12% of patients developed acute kidney injury. Forty-five MET + PBZ patients were propensity-matched with PBZ-only patients. Intraoperatively, MET + PBZ patients had lower minimum systolic and diastolic blood pressures than PBZ-only patients (median systolic, 74 vs 80 mm Hg, P = 0.01; median diastolic, 42 vs 46 mm Hg, P = 0.005) and larger intraoperative blood pressure oscillations (median systolic range, 112 vs 93 mm Hg, P = 0.06; median diastolic range, 58 vs 51 mm Hg, P = 0.02). Postoperative vasopressor infusion use was similar between MET + PBZ and PBZ only (16% vs 11%, P = 0.76). Major outcomes were not different between regimens.
CONCLUSION: Large hemodynamic oscillations were present in our PCC/PGL patients treated with MET + PBZ. These patients had a wider range of intraoperative blood pressure variations than PBZ-only patients. No differences in postoperative comorbid outcomes were found between MET + PBZ and PBZ-only groups.
Copyright © 2017 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Metyrosine; Paraganglioma; Phenoxybenzamine; Pheochromocytoma; α-adrenergic blockade

Mesh:

Substances:

Year:  2017        PMID: 28803996     DOI: 10.1016/j.ijsu.2017.08.026

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  8 in total

1.  A 15-year-old girl with a parotid mass and hypertension: Answers.

Authors:  Philip K Angelides; Clement D Lee; Stephanie Clark
Journal:  Pediatr Nephrol       Date:  2022-05-18       Impact factor: 3.651

2.  Epidural anesthesia and hypotension in pheochromocytoma and paraganglioma.

Authors:  Douglas Wiseman; James D McDonald; Dhaval Patel; Electron Kebebew; Karel Pacak; Naris Nilubol
Journal:  Endocr Relat Cancer       Date:  2020-09       Impact factor: 5.678

Review 3.  Recent advances in the management of pheochromocytoma and paraganglioma.

Authors:  Akiyo Tanabe; Mitsuhide Naruse
Journal:  Hypertens Res       Date:  2020-08-11       Impact factor: 3.872

4.  Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series.

Authors:  Atousa Deljou; Jacob D Kohlenberg; Toby N Weingarten; Irina Bancos; William F Young; Darrell R Schroeder; David P Martin; Juraj Sprung
Journal:  BMC Anesthesiol       Date:  2018-11-06       Impact factor: 2.217

Review 5.  Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance.

Authors:  Jan Calissendorff; Carl Christofer Juhlin; Irina Bancos; Henrik Falhammar
Journal:  Cancers (Basel)       Date:  2022-02-12       Impact factor: 6.639

6.  Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature.

Authors:  Irina Bancos; Elizabeth Atkinson; Charis Eng; William F Young; Hartmut P H Neumann
Journal:  Lancet Diabetes Endocrinol       Date:  2020-11-26       Impact factor: 32.069

7.  The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.

Authors:  Lucinda M Gruber; Sina Jasim; Allison Ducharme-Smith; Toby Weingarten; William F Young; Irina Bancos
Journal:  J Clin Endocrinol Metab       Date:  2021-05-13       Impact factor: 5.958

Review 8.  Preoperative Management of Pheochromocytoma and Paraganglioma.

Authors:  Fang Fang; Li Ding; Qing He; Ming Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-29       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.